Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Koene

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
European Journal of Clinical Nutrition|August 10, 2024
Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapyRianne van Lieshout, Lidwine W Tick, Erik A M Beckers, et al.
British Journal of Haematology|July 11, 2019
Rituximab-PECC induction followed by <sup>90</sup> Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON studyPieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, et al.
Haematologica|March 17, 2018
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Suzana Couto, et al.
Haematologica|September 8, 2022
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient populationCamille C B Kockerols, Jeroen J W M Janssen, Nicole M A Blijlevens, et al.
Blood Advances|January 8, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOSA Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, et al.
Clinical Nutrition ESPEN|March 7, 2025
Associations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: A multicenter prospective correlational studyRianne van Lieshout, Lidwine W Tick, Erik A M Beckers, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Leukemia & Lymphoma|September 14, 2012
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient programImane Abouyahya, Canan Alhan, Theresia M Westers, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
Experimental Hematology|August 12, 2020
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Lina van der Straten, Arnon P Kater, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
European Journal of Clinical Nutrition|August 10, 2024
Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapyRianne van Lieshout, Lidwine W Tick, Erik A M Beckers, et al.
British Journal of Haematology|July 11, 2019
Rituximab-PECC induction followed by <sup>90</sup> Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON studyPieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, et al.
Haematologica|March 17, 2018
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Suzana Couto, et al.
Haematologica|September 8, 2022
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient populationCamille C B Kockerols, Jeroen J W M Janssen, Nicole M A Blijlevens, et al.
Blood Advances|January 8, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOSA Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, et al.
Clinical Nutrition ESPEN|March 7, 2025
Associations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: A multicenter prospective correlational studyRianne van Lieshout, Lidwine W Tick, Erik A M Beckers, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Leukemia & Lymphoma|September 14, 2012
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient programImane Abouyahya, Canan Alhan, Theresia M Westers, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
Experimental Hematology|August 12, 2020
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Lina van der Straten, Arnon P Kater, et al.
Pageof 7